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Introduction
Cells in multicellular organisms communicate directly
with each other and such communications is mediated
by gap junctions [1,2]. Each gap junction channel is
consists of two connexons, a hexameric hemichannels
which belong to a certain family of structural proteins
called connexins (Cxs), and so far more than 20 differ-
ent connexin genes were identified in human [3]. Con-
nexons from two neighboring cells dock to the plasma
membrane and form an aqueous intercellular channel
that allow exchange of molecules and ions smaller
than 1kDa between cells. Gap junctional intercellular
communication (GJIC) plays a critical role in tissue
development, differentiation and cell proliferation and
is important in maintenance of tissue homeostasis.
Three Cxs have been detected in normal rodent
breast tissue: Cx26, Cx32 and Cx43 [4,5]. In normal
human breast Cx26 is present in breast epithelium
mostly between luminal cells of major ducts. Alveolar
structures are less immunoreactive for this kind of con-
nexin. An expression of Cx43 was revealed between
myoepithelial cells of ducts and a weaker immunore-
activity was associated with luminal/alveolar struc-
tures [6]. Cx32 was not detected in human breast [6].
GJIC is often impaired in the cancerous cells and at
tumor borders with a surrounding normal tissue, there-
fore decreased communication via gap junctions may
be an important event in oncogenesis. In many cases
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restoration or up-regulation of Cxs expression has
reduced tumor growth and promoted cell differentia-
tion [6,7]. Consequently, connexin genes have been
named tumor supressors. Many studies have so far
proved that the lack of connexins expression and/or the
function of gap junction channels is an early event in
tumorigenesis. The reduction of GJIC, besides the
decreased expression of Cxs, often is marked with an
aberrant localization of Cxs i.e. in the cytoplasm or
nucleus of cancerous cells.[8-10] The role of Cxs in
metastatic process is controversial, because some stud-
ies indicate that Cx expression is inversely correlated
to the metastatic capacity [11]. On the contrary, others
demonstrate that Cxs may be involved in metastasis.
Loss of GJIC could support growth of cancerous cells
as well as enhance heterogeneity within the tumor cell
population. In the breast cancer it has been shown that
disturbances of GJIC could provoke breast cancer cells
to metastasize [12]. In addition, loss of intercellular
communication correlated with high metastatic poten-
tial of mammary adenocarcinoma cells [11]. On the
other hand, there is a growing body of evidence that
Cxs may be involved in intravasation and extravasa-
tion of cancerous cells [13-15]. Nevertheless, it is still
unclear whether and how Cxs could participate in the
metastatic process of breast cancer especially to the
lymph nodes. As we known, Cx32 expression has been
not studied in human breast cancer. Consequently, the
aim of the present study was to evaluate the expression
of Cx32 in primary tumors and metastases to the
lymph nodes as well as to estimate the relationship
between assessed connexin and selected anatomoclin-
ical features.
Material and methods
Patients and tissue specimens. This study comprised 79 women
treated surgically with partial or total mastectomy and lymph node
dissection for primary breast cancer. The age of patients ranged
from 30 to 80 years, with a mean age of 54.6 years. Patients had
not received any preoperative chemo- or hormonotherapy. Tumor
samples, adjacent normal tissue and lymph nodes were collected
immediately after surgical removal of tumor, fixed in 10% buffered
formaldehyde solution for 48 hours and then embedded in paraffin
blocks at 56°C according to standard procedures. Tumor samples
were cut into 5 μm thick sections and stained with hematoxylin-
eosin. The diagnosis was based on the WHO and pTN classifica-
tion of breast tumors. Our study included only invasive ductal car-
cinomas, 53 (67.1%) cases in G2 grade and 26 (32.9%) cases in G3
grade. Tumor grade was assessed according to the Bloom and
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Fig. 1 Cx32 expression in primary tumor of breast cancer and matched-paired metastasis to the lymph node. (a,c) About half of all tumor
cells shows weak, cytoplasmic staining pattern. (b,d) In the lymph node, metastatic cells demonstrates strong granular immunostaining
for Cx32 in majority of cells (original magnification ×200).
Richardson's system [1]. 36/79 (45.6%) women had involved
lymph nodes at the time of diagnosis. 
Immunohistochemistry. Cx32 was investigated in 79 primary
tumors and 35 matched lymph node metastases and in 31 cases of
normal breast tissue and/or benign breast lesions adjacent to the
breast cancer using polyclonal goat Cx32 antibody (Ab) (Santa
Cruz Biotechnology, SCBt, USA) at dilution 1:300. Primary Ab
was diluted in PBS with 1.5% normal blocking serum. We applied
streptavidin-biotin-peroxidase complex technique to visualize the
complexes of connexin and their specific antibody (LSAB kit,
Dako, Denmark). Immunohistochemical method has been
described previously [18]. Slides were counterstained with haema-
toxylin. Two independent pathologists appreciated intensity of
developed immunoreactivity of connexins with the use of light
microscopy (Olympus BX40). In negative controls the primary
antibody was omitted in procedure of immunohistochemical stain-
ing. The expression of Cx32 was undetectable in the control sam-
ples, where immunostaining was performed with the omission of
the primary antibodies.
The expression of Cx32 was analyzed in 10 different tumor
fields and the presence of connexin was assessed according to a 3-
point scale: 0, <10% positive cells; 1+, 10-50% positive cells; 2+,
>50% positive cells. For statistical comparisons with selected clin-
icopathological features, the specimens were divided into groups
of connexin - positive (connexin expressed at level 1+ or 2+) and
connexin - negative (connexin expressed at level 0) tumors.
Statistical analysis. The associations of Cx32 with selected clini-
copathological features were evaluated using the chi-square test.
Differences in Cx32 expression between primary tumors and
lymph node metastases were assessed using Mann-Whitney U -
Wilcoxon Rank Sum W test. Probabilities of p<0.05 were assumed
as statistically significant.
Results
Expression of Cx32 in primary tumors.
In primary tumors (PTs), 31 of total 79 cancers
(39.2%) were positive for Cx32 and only cytoplasmic
expression of this protein was seen (Fig.1a, 1c). The
intensity of Cx32 immunostaining varied from low 1+
in 45.2% of Cx32-positive samples (14 of 31), to 2+ in
54.8% of Cx32-positive cases (17 of 31). Expression
of Cx32 was negative in almost all studied non-cancer
mammary glands directly bordering on primary breast
cancer. Only in a few cases of intraductal proliferative
lesions, focally positive cytoplasmic immunostaining
for Cx32 was observed.
Expression of Cx32 in lymph node metastases.
The positive expression of Cx32 was present in 26 of
35 matched lymph node metastases (MLNs) (74.3%).
Similarly to primary tumors only cytoplasmic staining
was observed (Fig.1b, c). The expression of Cx32 was
graded as 1+ (53.8% of Cx32-positive samples) or 2+
(46.2% of Cx32-positive samples).
Comparison of Cx32 expression between primary
tumors and matched lymph node metastases
To assess changes in the expression of Cx32, which
undergoes during breast cancer progression, the protein
was studied in 35 matched pairs of primary tumors and
metastases to lymph nodes (Table 1). In 14/35 (40%) of
the pairs we noted unchanged expression of Cx32 in
metastases to lymph nodes and primary tumors (Table1).
Increased intensity of immunoreactivity for Cx32 in
metastases relative to primary tumor was observed in 17
of 35 cases (48.6%). It is important to note that 15 of 21
(71.4%) Cx32-negative primary tumors developed
Cx32-positive metastases to regional lymph nodes, but
only 3 of 14 Cx32-positive primary tumors led to Cx32-
negative metastasis (Table 1). Statistical comparisons
(Mann-Whitney U - Wilcoxon Rank Sum W test) of
Cx32 expression in the matched pairs indicate that this
protein significantly increased in lymph node metastases
compared to primary tumors (p<0.001).
Analysis of correlations between Cx32 expression
and some clinicopathological features
The expression of Cx32 did not correlate significant-
ly with lymph node status, tumor size, histological
differentiation and age of patients (Table 2). In our
study we noted only a tendency toward association
between Cx32 expression and histological differenti-
ation (p=0.062; Table 2).
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Table 1. Comparison of Cx32 expression between the primary breast cancers and matching lymph node metastases.
Discussion
Expression of connexis in human breast epithelium
was examined in vitro and in vivo. Monaghan et al. [6]
revealed that luminal cells of human mammary gland
expressed Cx26 whereas the basal (myoepithelial)
cells expressed Cx43. Cx32 was not detected in human
mammary gland epithelium. However, expression of
Cx32 has been found in rodent mammary epithelium,
but only in lactating gland [5]. Decreased expression
of Cxs and alterations in GJIC were associated with
tumorigenesis [19-21]. Furthermore, restoration of Cx
expression and functional GJIC causes a change of
tumor cells to a more normal phenotype [6,22]. Con-
sequently, it is currently accepted that genes encoding
connexins could play a role of tumor suppressor. Wil-
genbus et al. [19] previously demonstrated a signifi-
cant decrease in gap-junction proteins in breast cancer
in comparison to normal tissue. These authors using
immunofluorescence technique evaluated Cxs expres-
sion in seven invasive breast carcinomas, but neither
Cx26 nor Cx43 was present in the parenchymal com-
ponent of studied tumors. On the other hand, Jamieson
et al. [10] found an increased but mainly cytoplasmic
immunostaining for Cx26 and Cx43 in breast cancer
cells, but expression of Cx32 in human breast cancer
cells was not studied as yet. In the present study, we
found Cx32 in breast cancer cells, but only cytoplas-
mic localization with microgranular staining for this
protein was seen. Cx32 was not present in the normal
mammary gland adjacent to the breast cancer. 
In many studies reporting decreased expression of
connexins in cancer, the investigators described mem-
branous staining for connexins, which is characteristic
of functional gap junctions. Cytoplasmic expression of
Cx32 observed in the present study may be an indirect
evidence of lack of functional gap junction channels
between cancerous cells, which was suggested in pre-
vious papers [10,11] and our recent reports [21,24]. It
is very probable that transformed cells have an ability
to produce Cxs also atypical for normal cells, but these
connexins are probably not assembled into functional
gap junction channels, however could play different
roles in breast cancer. Connexins which do not assem-
ble to functional gap junction channels could probably
modify the expression of different genes in coopera-
tion with other proteins and in this way could take part
in signaling pathways [25-27]. 
Growth suppression by Cxs in tumors is more
complex and could arise from other mechanisms than
GJIC. Inhibition of tumor growth by Cxs might be a
result of changes in expression of genes controlling
cell cycle, differentiation, apoptosis and angiogene-
sis. For instance, Qin et al. [28] found that tumor-
suppressing properties of connexins in breast cancer
cell lines were independent of gap junction commu-
nication. They suggested that it could be a result of
down-regulation of genes involved in tumor growth
such as gene encoding fibroblast growth factor recep-
tor-3 [28]. McLachlan et al. [29] shown that Cx26
and Cx43 may inhibit the malignant properties of
MDA-MB-231 breast cancer cells via GJIC-inde-
pendent mechanisms, including regulation of differ-
entiation and angiogenesis. Furthermore, recently
Kalra et al. [30] revealed that Cx26 inhibits breast
MDA-MB-435 cell tumorigenic properties by a gap
junctional intercellular communication-independent
mechanism through regulation the expression of
genes important in cell migration and invasion. Addi-
tionally, Chen et al. [25] demonstrated that in Cx43-
transfected malignant cells decreased expression of
cyclin/cyclin-dependent kinases is present. Potential
mechanism, suggested previously by Qin et al. [28],
responsible for these events is that connexins or con-
nexin fragments might regulate gene transcription,
possible by interactions with transcription factors.
Another possibility is that organelle-localized or
membrane-distributed hemichannels, which oligo-
merize by the secretory pathway, may be gated open
and allow the passage of secondary messengers.
However, further studies are needed to prove that
intracellular hemichannels can be open and partici-
pate in transition of signals to the nucleus and in reg-
ulation of gene transcription.
Metastasis of breast cancer is a multi-step process
that involves various mechanisms, but the factors pro-
moting metastasis are still not well known. It was sug-
gested that loss of gap junction expression and distur-
bance of gap junctional intercellular communication
would be important events in invasion and metastasis by
facilitating of the local invasion of primary tumors,
because the reduction of cell-cell communication could
contribute to cellular dissociation.[12,31,32] However,
the role of connexins (Cxs) in metastagenicity remains
controversial, because it is still unclear, whether con-
nexins expression is required for metastasizing.
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Table 2. Analysis of correlations between Cx32 expression and
some clinicopathological features.
In the present study, we found cytoplasmic micro-
granular staining for Cx32 in metastases to the lymph
nodes. Interestingly, we observed that expression of
Cx32 increase in lymph node metastases of breast can-
cer compared to primary tumors. Moreover, 15/21 of
Cx32-negative PTs (71.4%) developed positive
MLNs. These results are in agreement with our recent
report in which expression of Cx26 and Cx43 was
detected in primary breast tumors and matched lymph
node metastases [33]. In this paper we demonstrated
for the first time that expression of both Cx26 and
Cx43 increase in lymph node metastases of breast can-
cer compared to primary tumors. Furthermore, the
enhanced membranous immunostaining pattern of
Cx43 was found in metastases to lymph nodes, while
membranous Cx26 expression was appeared only in
metastatic breast cancer cells. Additionally, Cx26- and
Cx43-negative PTs developed Cx26- and Cx43-posi-
tive MLNs. Increased expression in metastatic sites
compared to primary tumors in our previous and pres-
ent findings is compatible with results of Kamibayashi
et al. [31]. In an immunohistochemical study on the
gap junction proteins Cx26 and Cx43 in different
stages of mouse skin carcinogenesis they revealed that,
even though locally invasive cancer cells showed little
expression of Cx26 and Cx43, in cells which metasta-
sized into lymph nodes very evident membranous
expression of Cx26 was found. 
It was supposed that connexins may play an
important role in the migration of cancerous cells into
lymphoid tissues through the vascular endothelium
by formation of heterocellular gap junctions between
tumor cells and endothelial cells in lymph node ves-
sels.[16,31] The other possible interpretation of our
results, which was also suggested by other authors
was that expression of connexins in lymph node
metastases may reflect higher degree of differentia-
tion of metastatic tumor cells compared with cancer
cells in the primary tumor [31,34]. Nevertheless,
these conclusions could explain membranous local-
ization of connexins in metastases to lymph nodes,
which was observed in both mentioned papers, but in
present paper we described only cytoplasmic Cx32
expression in metastatic lymph nodes. In this
instance, such findings may only reflect induction of
other connexin gene transcription also atypical to
normal breast epithelium and production of new pro-
tein, during breast carcinogenesis. Interestingly, we
also demonstrated that 15 of 21 (71.4%) Cx32-nega-
tive primary tumors developed Cx32-positive metas-
tases to regional lymph nodes. Possible explanation
of this phenomenon could be hypothesis that cells
capable to metastasizing must posses particular prop-
erties and only Cx-positive clones of cancerous cells
have metastatic potential. It is also possible that this
type of disruption in connexin protein production
might be a sign of more malignant phenotype of can-
cerous cells.
Taking account our and previous findings we sup-
pose that evaluation of other Cxs expression than Cx26
and Cx43 may extend our knowledge about expression
of this proteins during carcinogenesis in the human
breast. 
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